Ignite Creation Date:
2024-05-06 @ 7:46 PM
Last Modification Date:
2024-10-26 @ 3:13 PM
Study NCT ID:
NCT06126640
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-11-13
First Post:
2023-11-07
Brief Title:
A Phase III Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine T-DM1 in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Sponsor:
Jiangsu HengRui Medicine Co Ltd
Organization:
Jiangsu HengRui Medicine Co Ltd
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-11
Start Date Type:
ESTIMATED
Primary Completion Date:
2030-04
Primary Completion Date Type:
ESTIMATED
Completion Date:
2032-04
Completion Date Type:
ESTIMATED
First Submit Date:
2023-11-07
First Submit QC Date:
November 7 2023
Study First Post Date:
2023-11-13
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-11-07
Last Update Post Date:
2023-11-13
Last Update Post Date Type:
ACTUAL